Document is current
Any future updates will be listed below
-
Authors
Galimberti, Marco https://orcid.org/0000-0001-6052-156X
Overstreet, Cassie
Gupta, Priya
Beck, Sarah https://orcid.org/0000-0003-4176-2936
Dao, Cecilia
Deak, Joseph D. https://orcid.org/0000-0002-0540-6080
Zhou, Hang https://orcid.org/0000-0002-7694-6391
Johnson, Emma C. https://orcid.org/0000-0003-0394-777X
Agrawal, Arpana https://orcid.org/0000-0002-0313-793X
Stein, Murray B. https://orcid.org/0000-0001-9564-2871
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
- License Information
-
More Information
Article History
Received: 12 September 2024
Accepted: 22 April 2025
First Online: 29 May 2025
Competing interests
: J.G. is paid for editorial work for the journal Complex Psychiatry. M.B.S. has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sumitomo Pharma and Roche/Genentech. M.B.S. has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (editor-in-chief), Biological Psychiatry (deputy editor) and UpToDate (co-editor-in-chief for psychiatry). He has also received research support from NIH, Department of Veterans Affairs and the Department of Defense. He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. The other authors declare no competing interests.
